Cytokine Release Syndrome Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market

Cytokine Release Syndrome Market

DelveInsight has launched a new report on “Cytokine Release Syndrome – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Cytokine Release Syndrome – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Cytokine Release Syndrome, historical and forecasted epidemiology as well as the Cytokine Release Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Cytokine Release Syndrome Market Report:

• The total number of patients who develop Cytokine Release Syndrome following CART therapies in the 7MM was 3,371 in 2020.
• The total number of Hematologic malignancies [includes ALL, B-Cell NHL (DLBCL, FL, PMBCL etc.) & Multiple Myeloma] patients receiving CART-therapies in the 7MM were 4,389 in 2020. 
• Among the European 5 countries, Germany had the highest population of CRS with 199 cases, followed by France and the United Kingdom with 175 and 161 cases respectively. On the other hand, Spain had the lowest population of 90 cases in 2020. 
• Japan had 217 cases of Cytokine Release Syndrome in 2020, with the approval of Kymriah.

Key benefits of the report:

1. Cytokine Release Syndrome market report covers a descriptive overview and comprehensive insight of the Cytokine Release Syndrome Epidemiology and Cytokine Release Syndrome  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Cytokine Release Syndrome market report provides insights on the current and emerging therapies.
3. Cytokine Release Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Cytokine Release Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cytokine Release Syndrome market.

Cytokine Release Syndrome Overview

Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation. Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neuropsychiatric syndrome that can occur in some patients who are treated with immunotherapy and may or may not accompany CRS.

Cytokine Release Syndrome Market 

The dynamics of the Cytokine Release Syndrome market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, and others during the forecasted period 2018-2030.

Cytokine Release Syndrome Pipeline Therapies and Key Companies 

• Itacitinib: Incyte
• Anakinra & Axicabtagene Ciloleucel: Kite, A Gilead Company
• Defibrotide: Jazz Pharmaceuticals

Cytokine Release Syndrome Market Drivers 

• Increasing incidence of Acute cytokine release syndrome (CRS)

The recent approval and rise in the utilization of CAR T-cell therapies are leading to an increasing CRS patient population. 

• Increasing R&D activities

Basic research findings and investigations of patients with CRS will provide valuable insight into the underlying mechanisms of CRS. They could aid in the development of molecularly-targeted treatment strategies to prevent and treat CRS.

• Non-competitive landscape

Tocilizumab is the only United States Food and Drug Administration (USFDA) approved drug present in the market to date, for this indication. 

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Cytokine Release Syndrome Patient Share (%) Overview at a Glance

5. Cytokine Release Syndrome Market Overview at a Glance

6. Cytokine Release Syndrome Disease Background and Overview

7. Cytokine Release Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Cytokine Release Syndrome 

9. Cytokine Release Syndrome Current Treatment and Medical Practices

10. Unmet Needs

11. Cytokine Release Syndrome Emerging Therapies

12. Cytokine Release Syndrome Market Outlook

13. Country-Wise Cytokine Release Syndrome Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Cytokine Release Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Cytokine Release Syndrome Pipeline 

“Cytokine Release Syndrome Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cytokine Release Syndrome market. A detailed picture of the Cytokine Release Syndrome pipeline landscape is provided, which includes the disease overview and Cytokine Release Syndrome treatment guidelines.

Cytokine Release Syndrome Epidemiology

DelveInsight’s ‘Cytokine Release Syndrome  Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Cytokine Release Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/